İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024 · article

Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

YÖKSİS OpenAlex Açık erişim · hybrid Üst %10
Yıl2024
Atıf23OpenAlex
Yüzdelik%97,0
FWCI5,911,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıThe Journal of Allergy and Clinical Immunology: In Practice
  • Katalog eşleşmesi (ISSN)Journal of Allergy and Clinical Immunology: In Practice
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

BACKGROUND: Allergic rhinitis (AR) and asthma may affect health-related quality of life. However, national estimates on the quality of life of patients with AR or asthma are lacking. OBJECTIVE: To provide estimates for utility scores and EuroQoL five-dimension (EQ-5D) visual analog scale (VAS) for patients with AR or asthma. METHODS: We conducted a cross-sectional study using direct patient data from the MASK-air app on European MASK-air users with self-reported AR or asthma. We used a multi-attribute instrument (EQ-5D) to measure quality of life (as utility scores and EQ-5D VAS values). Mean scores were calculated per country and disease control level using multilevel regression models with poststratification, accounting for age and sex biases. RESULTS: We assessed data from 7905 MASK-air users reporting a total of up to 82,737 days. For AR, utilities ranged from 0.86 to 0.99 for good control versus 0.72 to 0.85 for poor control; EQ-5D VAS levels ranged from 78.9 to 87.9 for good control versus 55.3 to 64.2 for poor control. For asthma, utilities ranged from 0.84 to 0.97 for good control versus 0.73 to 0.87 for poor control; EQ-5D VAS levels ranged from 68.4 to 81.5 for good control versus 51.4 to 64.2 for poor control. Poor disease control was associated with a mean loss of 0.14 utilities for both AR and asthma. For the same control levels, AR and asthma were associated with similar utilities and EQ-5D VAS levels. However, lower values were observed for asthma plus AR compared with AR alone. CONCLUSIONS: Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

23atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 10 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2025 Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal TreatmentsAtıf 30 · OpenAlex
  2. 2025 Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal TreatmentsAtıf 30 · OpenAlex
  3. 2025 Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments.Atıf 30 · OpenAlex
  4. 2024 Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air StudyAtıf 28 · OpenAlex
  5. 2025 Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making AlgorithmsAtıf 11 · OpenAlex
  6. 2025 Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making AlgorithmsAtıf 11 · OpenAlex
  7. 2025 Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making AlgorithmsAtıf 11 · OpenAlex
  8. 2026 Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part II —Guidelines on Oral and Ocular TreatmentsAtıf 9 · OpenAlex
  9. 2025 Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK ‐air and EAACI Methodological Committee ReportAtıf 6 · OpenAlex
  10. 2025 Impact of allergic symptoms on work productivity in allergic rhinitis: A MASK-air direct patient data studyAtıf 6 · OpenAlex

Yazarlar

2
  1. BİLUN GEMİCİOĞLU İSTANBUL ÜNİVERSİTESİ-CERRAHPAŞA 1
  2. AYŞE ARZU YORGANCIOĞLU 2